tiprankstipranks
Gilead Sciences (CH:GILD)
NASDAQ:GILD
Switzerland Market
GILD
Gilead Sciences
RESEARCH TOOLSreports

Gilead Sciences (GILD) Stock News & Sentiment

4 Followers
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
Premium
Ratings
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
7d ago
GILD
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
Premium
Ratings
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
7d ago
GILD
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
Premium
Ratings
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
7d ago
GILD
Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio
Premium
Market News
Anthropic Finalizes $400 Million Takeover of AI Startup Coefficient Bio
12d ago
NVO
SNY
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
Premium
Market News
M&A News: Gilead Bets $2B+ on Ouro Medicines to Power Immunology Growth
22d ago
GSK
GILD
Buy Rating on Gilead Driven by HIV Franchise Momentum and Upside from Yeztugo and Biktarvy
Premium
Ratings
Buy Rating on Gilead Driven by HIV Franchise Momentum and Upside from Yeztugo and Biktarvy
23d ago
GILD
Gilead Ends Obeldesivir Filovirus Prophylaxis Trial: What It Means for GILD Investors
Premium
Company Announcements
Gilead Ends Obeldesivir Filovirus Prophylaxis Trial: What It Means for GILD Investors
25d ago
GILD
More CH:GILD News >

GILD News on the Web

Gilead put volume heavy and directionally bearish
TipRanks News
Neutral
Scotiabank Reaffirms Their Buy Rating on Gilead Sciences (GILD)
TipRanks News
Bullish
Gilead price target raised to $165 from $156 at Citi
TipRanks News
Bullish
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
CNBC
Neutral
Gilead Sciences (GILD) Projects $107M Impact on Q1 Earnings from Recent Acquisitions
GuruFocus News
Bullish
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
Zacks
Neutral
Gilead price target raised to $175 from $171 at Morgan Stanley
TipRanks News
Bullish
Morgan Stanley Reaffirms Their Buy Rating on Gilead Sciences (GILD)
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
CH:GILD
Sector Average
Media Buzz
This Week26 articles
Weekly Average20.25 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:GILD’s Media Buzz Sentiment?
26 articles about CH:GILD were published this week. In an average week, 20.25 articles are published.
    What is CH:GILD’s weekly average amount of articles?
    In an average week, 20.25 articles about CH:GILD are published.
      What is CH:GILD’s News Sentiment?
      100% of articles about CH:GILD were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week